Sulat takes charge at Maxygen

Maxygen CEO Russell Howard is leaving the company alongside CFO Lawrence Briscoe. Maxygen board member James Sulat, who had been CEO of Memory Pharmaceuticals, will fill their shoes beginning today. Story

Amsterdam Molecular Therapeutics named Jorn Aldag as its new CEO. Aldag, the former CEO of Evotec, has more than twenty five years of experience in corporate management and finance. Release

Sequenom CEO Harry Stylli was forced out of the company along with several other executives after an internal probe into the company's development of a new genetic test. Report

Amarillo Biosciences has appointed Bernard Cohen as chief financial officer. Release

Intrexon Corporation announced the appointment of Asher M. Rubin as executive vice president, chief legal officer and secretary. Release

Tianyin Pharmaceutical announced the appointment of Tao Yang to the position of chief operating officer. Release

Immunovaccine Technologies has appointed Gary Dodge, C.A., as chief financial officer. Release

Portola Pharmaceuticals announced executive promotions on the senior management team. William Lis, vice president, business & commercial development, has been promoted to the newly created position of chief operating officer. In this role, he will have responsibility for corporate development, clinical development and pharmaceutical development; Daniel D. Gretler, M.D., vice president, clinical development and regulatory affairs, has been appointed chief medical officer; Joseph Lambing, Ph.D., vice president, pharmaceutical development, has been promoted to senior vice president, pharmaceutical development; David R. Phillips, Ph.D., senior vice president, biology, has been named chief scientific officer. In this role, he will continue as head of biology and will grow the scientific advisory board to accommodate Portola's expanding product portfolio. Release

PHT Corp. promoted company executive Dwight Cooper to vice president of client services. Release

Catalent Pharma Solutions has named Will Downie in a dual role as group president, sterile technologies and senior vice president of global sales and marketing. Release

Tennessee biotechnology association named new board members. They are: Richard Magid, Ph.D., vice president at the University of Tennessee Research Foundation at the UT Health Science Center; Bob Morris, an AV-rated Martindale-Hubbell attorney and a partner with the Butler Snow law firm; Kenneth "Pete" Moss, president and managing partner of Frazier, Barnes & Associates; Jeff Smith, CPA, a partner in Ernst & Young's Nashville office; Ken Woody, former Army officer, entrepreneur and a Fortune 500 executive. Release

Nile Therapeutics named Arie S. Belldegrun, M.D., FACS to its board of directors. Release

Peter Fellner was nominated to be elected to Biotie's board of directors. Release

Sirona Biochem announced the first major appointment to its Scientific Advisory Board: patent lawyer Jacques Warcoin, CEO of Cabinet Regimbeau in Paris, France.  Release

Alexza Pharmaceuticals named Andrew L. Busser to its board of directors. Release

Yon Yoon Jorden, former chief financial officer of four publicly traded companies, and Todd Vannucci, managing director with Morgan Stanley & Co., have joined the board of directors of US Oncology. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.